Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …

This review provides a brief overview of the development of data‐independent acquisition
(DIA) mass spectrometry‐based proteomics and selected DIA data analysis tools. Various …

Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the
disease's biology and accelerated targeted therapy. However, the proteomic characteristics …

Sharing of research data in public repositories has become best practice in academia. With
the accumulation of massive data, network bandwidth and storage requirements are rapidly …

Mass spectrometry-based proteomic technique has become indispensable in current
exploration of complex and dynamic biological processes. Instrument development has …

Background As the most abundant epigenetic modification on mRNAs and long non‐coding
RNAs, N6‐methyladenosine (m6A) modification extensively exists in mammalian cells …

Metabolic reprogramming is a hallmark of cancer. However, it is not well known how
metabolism affects cancer progression. We identified that metabolic enzyme acyl-CoA …

Esophageal cancer (EC) is a type of aggressive cancer without clinically relevant molecular
subtypes, hindering the development of effective strategies for treatment. To define …

Chemotherapy and targeted therapy are the major treatments for gastric cancer (GC), but
drug resistance limits its effectiveness. Here, we profile the proteome of 206 tumor tissues …

Background Urothelial carcinoma (UC) is the most common pathological type of bladder
cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC …